Comparing Autonomix Medical (NASDAQ:AMIX) and Perspective Therapeutics (NYSE:CATX)

Perspective Therapeutics (NYSE:CATX) and Autonomix Medical (NASDAQ:AMIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Perspective Therapeutics and Autonomix Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%
Autonomix Medical	N/A	-542.11%	-236.92%

Valuation and Earnings

This table compares Perspective Therapeutics and Autonomix Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	$1.43 million	206.55	-$46.51 million	N/A	N/A
Autonomix Medical	N/A	N/A	-$15.43 million	($16.07)	-0.37

Autonomix Medical has lower revenue, but higher earnings than Perspective Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Perspective Therapeutics and Autonomix Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	1	8	0	2.89
Autonomix Medical	0	0	1	0	3.00

Perspective Therapeutics presently has a consensus target price of $15.14, indicating a potential upside of 246.52%. Autonomix Medical has a consensus target price of $28.00, indicating a potential upside of 366.67%. Given Autonomix Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Autonomix Medical is more favorable than Perspective Therapeutics.

Insider & Institutional Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by insiders. Comparatively, 32.4% of Autonomix Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.